| Schedule of financial information by reportable segment |
The following is financial information relating to the Company's reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
Nine Months Ended |
|
|
March 31, |
|
March 31, |
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
Net sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Protein Sciences segment revenue |
|
$ |
227,687 |
|
$ |
214,589 |
|
$ |
643,774 |
|
$ |
616,914 |
Diagnostics and Spatial Biology segment revenue |
|
|
89,231 |
|
|
87,511 |
|
|
256,558 |
|
|
235,715 |
Other revenue(1) |
|
|
— |
|
|
2,093 |
|
|
4,152 |
|
|
2,093 |
lntersegment revenue |
|
|
(737) |
|
|
(765) |
|
|
(1,813) |
|
|
(1,761) |
Consolidated revenue |
|
$ |
316,181 |
|
$ |
303,428 |
|
$ |
902,671 |
|
$ |
852,961 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
Protein Sciences segment operating income |
|
$ |
103,910 |
|
$ |
94,829 |
|
$ |
271,564 |
|
$ |
262,777 |
Diagnostics and Spatial Biology segment operating income |
|
|
8,423 |
|
|
8,104 |
|
|
15,940 |
|
|
13,189 |
Segment operating income |
|
$ |
112,333 |
|
$ |
102,933 |
|
$ |
287,504 |
|
$ |
275,966 |
Cost recognized upon sale of acquired inventory |
|
|
(181) |
|
|
(186) |
|
|
(554) |
|
|
(550) |
Amortization of intangibles |
|
|
(18,836) |
|
|
(19,287) |
|
|
(57,136) |
|
|
(58,908) |
Acquisition related expenses and other |
|
|
(4,978) |
|
|
(3,286) |
|
|
(8,497) |
|
|
(2,173) |
Certain litigation charges |
|
|
(38,927) |
|
|
— |
|
|
(40,606) |
|
|
— |
(Impairment) recovery of assets held-for-sale |
|
|
3,655 |
|
|
— |
|
|
3,655 |
|
|
(6,038) |
Stock-based compensation, inclusive of employer taxes |
|
|
(11,629) |
|
|
(8,358) |
|
|
(37,504) |
|
|
(32,810) |
Restructuring and restructuring-related costs |
|
|
(716) |
|
|
(1,550) |
|
|
(15,027) |
|
|
(7,157) |
Corporate general, selling, and administrative |
|
|
(2,013) |
|
|
(3,346) |
|
|
(5,241) |
|
|
(7,545) |
Impact of business held-for-sale(1) |
|
|
— |
|
|
78 |
|
|
(479) |
|
|
78 |
Consolidated operating income |
|
$ |
38,708 |
|
$ |
66,998 |
|
$ |
126,115 |
|
$ |
160,863 |
(1) Includes the quarterly results of a business that has met the held-for-sale criteria since December 31, 2023.
|